Patents by Inventor Kenneth W. Kinzler
Kenneth W. Kinzler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240148870Abstract: Provided herein are immune cells and methods of use, wherein the immune cells include a chimeric antigen receptor (CAR), wherein the CAR comprises an extracellular antigen binding domain that binds specifically to a first epitope; and an inhibitory chimeric antigen receptor (iCAR), wherein the iCAR comprises an extracellular antigen binding domain that binds specifically to a second epitope, wherein the immune cell is activated when the immune cells binds to the first epitope and does not bind to the second epitope; and wherein the immune cell is inactivated when the immune cell binds to the first and second epitopes.Type: ApplicationFiled: March 11, 2022Publication date: May 9, 2024Inventors: Michael S. Hwang, Jacqueline Douglass, Emily Han-Chung Hsiue, Kenneth W. Kinzler, Brian J. Mog, Nickolas Papadopoulos, Alexander H. Pearlman, Bert Vogelstein, Shibin Zhou
-
Publication number: 20240124608Abstract: This document relates to methods and materials for treating T cell cancers. For example, a composition containing one or more bispecific molecules targeting T cell receptor £ chain constant region (TRBC) can be administered to a mammal having a T cell cancer to treat the mammal. For example, this document provides methods and materials for using one or more bispecific molecules to treat a mammal having a T cell cancer.Type: ApplicationFiled: February 15, 2022Publication date: April 18, 2024Inventors: Michael S. Hwang, Kenneth W. Kinzler, Brian J. Mog, Nickolas Papadopoulos, Andrew M. Pardoll, Suman Paul, Bert Vogelstein, Shibin Zhou
-
Publication number: 20240102092Abstract: The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Though massively parallel sequencing instruments are in principle well-suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. One example of this approach, called “Safe-SeqS” for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant (“super-mutants”) if ?95% of them contain the identical mutation.Type: ApplicationFiled: November 27, 2023Publication date: March 28, 2024Inventors: Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Isaac A. Kinde
-
Publication number: 20240084381Abstract: The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Though massively parallel sequencing instruments are in principle well-suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. One example of this approach, called “Safe-SeqS” for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant (“super-mutants”) if ?95% of them contain the identical mutation.Type: ApplicationFiled: November 13, 2023Publication date: March 14, 2024Inventors: Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Isaac A. Kinde
-
Publication number: 20240045844Abstract: A method for classifying data using non-negative matrix factorization can include receiving a population of sample data, generating a first matrix of the amplicon counts per sample data, dividing the first matrix into a product of a second matrix and a third matrix, in the second matrix, determining whether each signature is a long or short fragment per each amplicon count, in the third matrix, determining intensities of each signature per the sample data, and classifying the sample data based on the intensities of each signature. The population can include amplicon counts per sample data. The second matrix can include signatures of short and long DNA fragments and the third matrix can include intensities of each signature of the short and long DNA fragments.Type: ApplicationFiled: October 1, 2021Publication date: February 8, 2024Inventors: Christopher Douville, Haley Grant, Albert Kuo, Kamel Lahouel, Kenneth W. Kinzler, Nickolas Papadopoulos, Cristian Tomasetti, Bert Vogelstein
-
Publication number: 20240002948Abstract: DNA containing somatic mutations is highly tumor specific and thus, in theory, can provide optimum markers. However, the number of circulating mutant gene fragments is small compared to the number of normal circulating DNA fragments, making it difficult to detect and quantify them with the sensitivity required for meaningful clinical use. We apply a highly sensitive approach to quantify circulating tumor DNA (ctDNA) in body samples of patients. Measurements of ctDNA can be used to reliably monitor tumor dynamics in subjects with cancer, especially those who are undergoing surgery or chemotherapy. This personalized genetic approach can be generally applied.Type: ApplicationFiled: January 23, 2023Publication date: January 4, 2024Inventors: Frank Diehl, Luis Diaz, Kenneth W. Kinzler, Bert Vogelstein, Kerstin Schmidt
-
Publication number: 20240002541Abstract: This document relates to methods and materials for treating T cell cancers. For example, a composition containing one or more bispecific molecules can be administered to a mammal having a T cell cancer to treat the mammal. For example, methods and materials for using one or more bispecific molecules to treat a mammal having a T cell cancer are provided.Type: ApplicationFiled: December 1, 2021Publication date: January 4, 2024Inventors: Sarah DiNapoli, Jacqueline Douglass, Emily Han-Chung Hsiue, Michael S. Hwang, Kenneth W. Kinzler, Maximilian Konig, Brian J. Mog, Nickolas Papadopoulos, Andrew M. Pardoll, Suman Paul, Alexander H. Pearlman, Bert Vogelstein, Shibin Zhou
-
Publication number: 20230365677Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.Type: ApplicationFiled: July 20, 2023Publication date: November 16, 2023Inventors: Luis Diaz, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Dung Le, Drew M. Pardoll, Suzanne L. Topalian
-
Patent number: 11807662Abstract: This document provides methods and materials for assessing a mammal having or suspected of having cancer and/or for treating a mammal having cancer. For example, molecules including one or more antigen-binding domains (e.g., a single-chain variable fragment (scFv)) that can bind to a modified peptide (e.g., a tumor antigen), as well as method for using such molecules, are provided.Type: GrantFiled: May 16, 2018Date of Patent: November 7, 2023Assignee: The Johns Hopkins UniversityInventors: Emily Han-Chung Hsiue, Qing Wang, Bert Vogelstein, Kenneth W. Kinzler, Shibin Zhou, Jacqueline Douglass, Michael S. Hwang, Nickolas Papadopoulos
-
Publication number: 20230338297Abstract: The present disclosure provides compositions comprising at least one cyclodextrin and at least one cytotoxic receptor binding small-molecule. Also disclosed are kits containing said compositions. The compositions of the present disclosure can be administered to a subject suffering from at least one type of cancer.Type: ApplicationFiled: August 31, 2021Publication date: October 26, 2023Inventors: Jordina RINCON-TORROELLA, Bert Vogelstein, Kenneth W. Kinzler, Shibin Zhou, Nickolas Papadopoulos, Marco Dal Molin, Surojit SUR
-
Publication number: 20230310549Abstract: This document relates to methods and materials for preventing cytokine release syndrome (CRS). For example, methods and materials for using one or more catecholamine inhibitors to prevent a mammal from developing CRS are provided.Type: ApplicationFiled: December 9, 2022Publication date: October 5, 2023Inventors: Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Shibin Zhou, Verena Staedtke, Renyuan Bai, Gregory J. Riggins
-
Patent number: 11773440Abstract: The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Though massively parallel sequencing instruments are in principle well-suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. One example of this approach, called “Safe-SeqS” for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant (“super-mutants”) if ?95% of them contain the identical mutation.Type: GrantFiled: April 28, 2021Date of Patent: October 3, 2023Assignee: The Johns Hopkins UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Isaac A. Kinde
-
Patent number: 11753468Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.Type: GrantFiled: September 26, 2022Date of Patent: September 12, 2023Assignee: The Johns Hopkins UniversityInventors: Luis Diaz, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Dung Le, Drew M. Pardoll, Suzanne L. Topalian
-
Publication number: 20230250483Abstract: The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.Type: ApplicationFiled: October 28, 2022Publication date: August 10, 2023Inventors: Isaac Kinde, Kenneth W. Kinzler, Bert Vogelstein, Nickolas Papadopoulos, Luis Diaz, Chetan Bettegowda, Yuxuan Wang
-
Patent number: 11718668Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.Type: GrantFiled: May 9, 2022Date of Patent: August 8, 2023Assignee: The Johns Hopkins UniversityInventors: Luis Diaz, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Dung Le, Drew M. Pardoll, Suzanne L. Topalian
-
Patent number: 11667976Abstract: TERT promoter mutations occur in both papillary and flat lesion bladder cancers, are the most frequent genetic alterations identified to date in noninvasive precursor lesions of the bladder, are detectable in urine, and appear to be strongly associated with bladder cancer recurrence. The TERT promoter mutations are useful urinary biomarker for both the early detection and monitoring of bladder neoplasia.Type: GrantFiled: November 13, 2020Date of Patent: June 6, 2023Assignee: The Johns Hopkins UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, Luis Diaz, Nickolas Papadopoulos, George J. Netto, Ralph Hruban, Isaac A. Kinde
-
Patent number: 11649287Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.Type: GrantFiled: September 2, 2021Date of Patent: May 16, 2023Assignee: The Johns Hopkins UniversityInventors: Luis Diaz, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Dung Le, Drew M. Pardoll, Suzanne L. Topalian
-
Patent number: 11643462Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.Type: GrantFiled: June 22, 2021Date of Patent: May 9, 2023Assignee: The Johns Hopkins UniversityInventors: Luis Diaz, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Dung Le, Drew M. Pardoll, Suzanne L. Topalian
-
Patent number: 11634491Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.Type: GrantFiled: May 9, 2022Date of Patent: April 25, 2023Assignee: The Johns Hopkins UniversityInventors: Luis Diaz, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Dung Le, Drew M. Pardoll, Suzanne L. Topalian
-
Patent number: 11628204Abstract: This document provides methods and materials for preventing cytokine release syndrome (CRS). For example, methods and materials for using one or more catecholamine inhibitors to prevent a mammal from developing CRS are provided.Type: GrantFiled: December 11, 2018Date of Patent: April 18, 2023Assignee: The Johns Hopkins UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Shibin Zhou, Verena Staedtke, Renyuan Bai, Gregory J. Riggins